Praziquantel–Clays as Accelerated Release Systems to Enhance the Low Solubility of the Drug
Open Access
- 23 September 2020
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 12 (10), 914
- https://doi.org/10.3390/pharmaceutics12100914
Abstract
Praziquantel is an antiparasitic drug indicated for the treatment of the schistosomiasis disease. This drug has very low aqueous solubility, requiring high oral doses for its administration which gives rise to side effects, therapeutic noncompliance and the appearance of resistant forms of the parasite. Clay minerals, like sepiolite and montmorillonite, are innocuous, non-toxic, biocompatible and low-cost excipients. Additionally, clays have high adsorbent properties that allow them to encapsulate drugs in nanometric spaces present in the channels in the case of the sepiolite or between the layers in the case of the montmorillonite. The interactions between the drug and clay minerals are studied experimentally with the strategy for preparing interactions products in organic solvents (ethanol, acetonitrile and dichloromethane) so that the interaction will be more effective and will be enhanced the aqueous solubility of praziquantel. The results showed that in the interaction products, the drug interacted with both clay minerals, which produced the loss of the crystallinity of the drug demonstrated by different techniques. This led to a significant increase in the dissolution rate of the praziquantel in all the interaction products in the simulated gastrointestinal tract media, except for the praziquantel–montmorillonite product prepared in dichloromethane that presented a controlled release in acid medium. Moreover, in vitro cytotoxicity and cell cycle studies were performed in the interaction products prepared with ethanol. The interaction product with sepiolite was biocompatible with the HTC116 line cells, and it did not produce alterations in the cell cycle. However, interaction products with montmorillonite did not produce cell death, but they showed affectation and damage of cells in the cell cycle study at the highest concentration tested (20–100 µM). Therefore, the different organic solvents used are adequate for the improvement of the biopharmaceutical profile of praziquantel. Drug–clay interaction products, specifically with sepiolite, showed very promising results in which new accelerated oral release systems of the praziquantel were obtained.Keywords
This publication has 45 references indexed in Scilit:
- Susceptibility or resistance of praziquantel in human schistosomiasis: a reviewZeitschrift Fur Parasitenkunde-Parasitology Research, 2012
- Current challenges in clay minerals for drug deliveryApplied Clay Science, 2010
- Effect of Cyclodextrin Complexation on the Aqueous Solubility and Solubility/Dose Ratio of PraziquantelAAPS PharmSciTech, 2009
- Summary of Recommendations of Nomenclature Committees Relevant to Clay Mineralogy: Report of the Association Internationale Pour l’Etude Des Argiles (AIPEA) Nomenclature Committee for 2006Clays and Clay Minerals, 2006
- Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at riskThe Lancet Infectious Diseases, 2006
- Structural characterization and enantioseparation of the chiral compound praziquantelJournal of Pharmaceutical Sciences, 2004
- Near-infrared and mid-infrared spectroscopic study of sepiolites and palygorskitesVibrational Spectroscopy, 2001
- Preparation, Dissolution and Characterization of Praziquantel Solid Dispersions.CHEMICAL & PHARMACEUTICAL BULLETIN, 1999
- Praziquantel: mechanisms of anti-schistosomal activityPharmacology & Therapeutics, 1985
- A new look at the statistical model identificationIEEE Transactions on Automatic Control, 1974